EFFECT OF BUSCOPAN COMPARED WITH GLUCAGON DURING GASTROSCOPY, COLONOSCOPY, AND ERCP- A NARRATIVE REVIEW

Objective: To provide a comprehensive overview of Buscopan and glucagon, comparing their mechanisms, efficacy, safety profiles, and guidelines for use in gastrointestinal endoscopy and ERCP. This review aims to offer insights into the optimal use of these agents, emphasizing the importance of personalized medicine in endoscopic practice. A narrative review was conducted, analyzing studies, clinical trials, and guidelines from prominent gastroenterological associations, including the Canadian Association of Gastroenterology (CAG) and the British Society of Gastroenterology (BSG) to compare the effects and efficacy of Buscopan and Glucagon. Buscopan is effective in enhancing visualization and reducing patient discomfort during endoscopic procedures. However, its use is contraindicated in certain conditions such as angle-closure glaucoma and with specific drug interactions. The CAG recommends against its routine use in gastroscopy and colonoscopy but acknowledges its benefits in ERCP (Endoscopic Retrograde Cholangiopancreatography). Glucagon, with a rapid onset and short half-life, is a viable alternative, particularly for patients who cannot use Buscopan. It has minimal side effects but requires careful management of potential hyperglycemia. Buscopan remains the preferred choice for spasmolysis in endoscopic procedures due to its efficacy and cost-effectiveness. Glucagon serves as an important alternative in cases where Buscopan is contraindicated. Personalized medicine, considering individual patient needs and potential risks, is essential in optimizing the use of these agents in gastrointestinal endoscopy. This review highlights the need for clinicians to carefully select and dose these spasmolytic agents to enhance patient safety, comfort, and procedural outcomes.